The purpose of the present invention is to provide an oral composition that possesses an excellent teeth remineralization promoting effect and that is capable of effectively promoting teeth remineralization even when retained in the oral cavity for a short period of time. An oral composition in which (A) a calcium salt of organic acid, (B) a fluoride, and (C) a basic peptide and/or a basic protein in which 60% or more of the constituent amino acid residues are basic amino acid residues are added in combination is capable of dramatically promoting teeth remineralization as a result of a synergetic effect of these components and is capable of effectively promoting teeth remineralization even when retained in the oral cavity for a short period of time.

The present invention provides: a complex of a mercaptoundecahydrodecaborate (BSH) and a peptide, the complex for boron neutron capture therapy (BNCT); a method for producing the complex; and a cancer therapy using the complex.

Glass-based particles of a biocompatible material which comprises 40 to about 80 wt % borate (B.sub.2O.sub.3) intermixed into a carrier which is an ointment, cream, or surgical glue.

Glass-based particles of a biocompatible material which comprises 40 to about 80 wt % borate (B.sub.2O.sub.3) intermixed into a carrier which is an ointment, cream, or surgical glue.

A method for binding an active substance or an active agent to an activated autologous blood nosode comprises a) dissolving blood of a patient in an aqueous or aqueous/ethanol medium or triturating blood of a patient with an excipient approved for globules according to HAB [Homeopathic Pharmacopoeia] in order to obtain a first mixture; b) activating the first mixture by exposure of the first mixture to magnetic pulses having frequencies of the magnet field periods within a range from approximately 0.01 to approximately 20,0000 Hz and maximum field strengths of 50 T; c) adding an active substance and/or active agent or one or more active substances and/or active agents to the activated first mixture in order to obtain a second mixture; d) succussing the second mixture by mechanical action, wherein steps c) and d) are conducted under the continuous action of the magnetic pulses, and wherein steps c) and d) can be repeated once or several times; and e) activating the succussed second mixture by further continuous exposure to the magnetic pulses and by irradiation with visible light of changing colors produced by LEDs into the succussed second mixture, whereby an increase of the binding capacity of the HSA [human serum albumin] in the blood to the active substance(s) and/or to at least some of the active agent or active agents is achieved. A device for performing the method is also described.

A method for binding an active substance or an active agent to an activated autologous blood nosode comprises a) dissolving blood of a patient in an aqueous or aqueous/ethanol medium or triturating blood of a patient with an excipient approved for globules according to HAB [Homeopathic Pharmacopoeia] in order to obtain a first mixture; b) activating the first mixture by exposure of the first mixture to magnetic pulses having frequencies of the magnet field periods within a range from approximately 0.01 to approximately 20,0000 Hz and maximum field strengths of 50 T; c) adding an active substance and/or active agent or one or more active substances and/or active agents to the activated first mixture in order to obtain a second mixture; d) succussing the second mixture by mechanical action, wherein steps c) and d) are conducted under the continuous action of the magnetic pulses, and wherein steps c) and d) can be repeated once or several times; and e) activating the succussed second mixture by further continuous exposure to the magnetic pulses and by irradiation with visible light of changing colors produced by LEDs into the succussed second mixture, whereby an increase of the binding capacity of the HSA [human serum albumin] in the blood to the active substance(s) and/or to at least some of the active agent or active agents is achieved. A device for performing the method is also described.

Stannous fluoride polyol solid solutions combine three complimentary, biochemical mechanisms attributed to Sn.sup.++, F.sup. and Polyol, respectively to reduce growth and metabolism of Streptococcus mutans while effecting superior Bioactivity Quotients. The stannous fluoride polyol solid solution particulate compositions of the present invention comprise: (a) stannous fluoride at between about 0.01 and about 0.8% by weight; (b) a polyol at between about 0.1 and about 30% by weight; (c) an astringency neutralizer at between about 0.01 and about 0.4% by weight, where the ratio of astringency neutralizer to stannous fluoride is from between about 0.01 and about 0.2; (d) a mucoadhesive at between about 1.5 and about 70% by weight, wherein the ratio of mucoadhesive to stannous fluoride polyol is from between about 7 to 1 and about 25 to 1; (e) a pH stabilizer, selected from the group consisting of malic, fumaric, citric acid and combinations thereof, wherein the ratio of pH stabilizer to stannous fluoride polyol is from between about 0.03 and 5 and preferably from between about 0.1 and about 3; and
(f) optional flavorants, stabilizers, preservatives, conditioners, and oral care adjuncts.

Stannous fluoride polyol solid solutions combine three complimentary, biochemical mechanisms attributed to Sn.sup.++, F.sup. and Polyol, respectively to reduce growth and metabolism of Streptococcus mutans while effecting superior Bioactivity Quotients. The stannous fluoride polyol solid solution particulate compositions of the present invention comprise: (a) stannous fluoride at between about 0.01 and about 0.8% by weight; (b) a polyol at between about 0.1 and about 30% by weight; (c) an astringency neutralizer at between about 0.01 and about 0.4% by weight, where the ratio of astringency neutralizer to stannous fluoride is from between about 0.01 and about 0.2; (d) a mucoadhesive at between about 1.5 and about 70% by weight, wherein the ratio of mucoadhesive to stannous fluoride polyol is from between about 7 to 1 and about 25 to 1; (e) a pH stabilizer, selected from the group consisting of malic, fumaric, citric acid and combinations thereof, wherein the ratio of pH stabilizer to stannous fluoride polyol is from between about 0.03 and 5 and preferably from between about 0.1 and about 3; and
(f) optional flavorants, stabilizers, preservatives, conditioners, and oral care adjuncts.

The present invention relates to improved biocide compositions based on calcium fluoride which are suitable for a broad range of applications including surface disinfectants, additives to construction materials and paints, antiseptic medical and cosmetic formulations, as a crop protection product and as a fast-acting disinfectant. The biocide composition of the invention comprise at least the following components: a) calcium fluoride b) a salicylic acid ester c) at least one organic acid selected from the group comprising or consisting of cinnamic acid, rosmarinic acid, vanillic acid, ascorbic acid, abscisic acid, mandelic acid, mevalonic acid, aspartic acid, salicylic acid, fumaric acid, isocitric acid, gallic acid, quinic acid, boswellic acid, carnosic acid, chlorogene acid, caffeic acid, other hydroxycarboxylic acids, or a salt or ester thereof, or thymol or citronellal. d) a cationic polymer and/or natural sea salt or a synthetic equivalent thereof and/or a cationic tenside, e) water. In preferred embodiments, the cationic polymer is selected from the group comprising or consisting of a poly(alkylene)guanidin or -biguanidin, or octenidin, and the organic acid is cinnamic acid and/or quinic acid.

The present invention relates to improved biocide compositions based on calcium fluoride which are suitable for a broad range of applications including surface disinfectants, additives to construction materials and paints, antiseptic medical and cosmetic formulations, as a crop protection product and as a fast-acting disinfectant. The biocide composition of the invention comprise at least the following components: a) calcium fluoride b) a salicylic acid ester c) at least one organic acid selected from the group comprising or consisting of cinnamic acid, rosmarinic acid, vanillic acid, ascorbic acid, abscisic acid, mandelic acid, mevalonic acid, aspartic acid, salicylic acid, fumaric acid, isocitric acid, gallic acid, quinic acid, boswellic acid, carnosic acid, chlorogene acid, caffeic acid, other hydroxycarboxylic acids, or a salt or ester thereof, or thymol or citronellal. d) a cationic polymer and/or natural sea salt or a synthetic equivalent thereof and/or a cationic tenside, e) water. In preferred embodiments, the cationic polymer is selected from the group comprising or consisting of a poly(alkylene)guanidin or -biguanidin, or octenidin, and the organic acid is cinnamic acid and/or quinic acid.